| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Lucidin primeveroside does not have a defined biological target for therapeutic use. It is an anthraquinone glycoside with demonstrated anti-inflammatory, antimicrobial, and cytotoxic properties. The compound may interact with various cellular targets, but its primary mechanism of action is associated with its metabolism to lucidin, a genotoxic compound that can form DNA adducts. It is used as a reference standard in genotoxicity and natural dye research.
|
|---|---|
| ln Vitro |
In vitro, Lucidin primeveroside has demonstrated anti-inflammatory, antimicrobial, and cytotoxic properties. It has been shown to induce lucidin-specific DNA adduct formation in cells. The compound's cytotoxic effects may be related to its metabolism to lucidin and subsequent DNA damage. However, detailed in vitro activity data, including IC₅₀ values and specific mechanisms, are not extensively documented in the publicly available literature.
|
| ln Vivo |
In mice, Lucidin primeveroside (0.3% in the diet; 4 weeks or 13 weeks) increases the frequency of mutations and causes the creation of Lucidin-specific DNA adducts[1].
In vivo, Lucidin primeveroside (0.3% in the diet; 4 weeks or 13 weeks) has been shown to induce lucidin-specific DNA adduct formation and increase mutation frequencies in mice. These findings raise concerns about the compound's genotoxic and carcinogenic potential. The compound's metabolism to lucidin in vivo is responsible for its genotoxic effects. It is not used for therapeutic purposes and is primarily a research compound. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Lucidin primeveroside are not typically conducted, as it is primarily a research compound and a reference standard. Studies have focused on its metabolism to lucidin and the formation of DNA adducts. The compound's genotoxicity is assessed using standard mutagenicity assays such as the Ames test or comet assay. Its anti-inflammatory and antimicrobial activities may be evaluated in appropriate biochemical assays.
|
| Cell Assay |
Lucidin primeveroside may be used in cell-based assays to evaluate its cytotoxic, anti-inflammatory, and antimicrobial activities. Cells may be treated with the compound to assess its effects on cell viability, inflammation markers, or microbial growth. Its genotoxicity can be assessed by measuring DNA adduct formation or using comet assays. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media are employed.
|
| Animal Protocol |
In vivo animal studies with Lucidin primeveroside have been conducted to assess its genotoxicity and carcinogenic potential. In mice, dietary administration of the compound at 0.3% for 4 or 13 weeks induced lucidin-specific DNA adduct formation and increased mutation frequencies. These studies highlight the compound's potential safety concerns. It is not used for therapeutic purposes and is primarily a research compound.
|
| ADME/Pharmacokinetics |
Lucidin primeveroside has a molecular formula of C₂₆H₂₈O₁₄ and a molecular weight of approximately 564.49 g/mol. It is a naturally occurring anthraquinone glycoside found in madder root. The compound has been used as a coloring agent and food additive. It has demonstrated anti-inflammatory, antimicrobial, and cytotoxic properties but also raises genotoxicity concerns. It is typically stored under conditions recommended for research chemicals.
|
| Toxicity/Toxicokinetics |
Lucidin primeveroside is intended for research use only and is not approved for human therapeutic applications. The compound has raised concerns due to potential genotoxic and carcinogenic effects associated with its metabolism to lucidin. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| References |
|
| Additional Infomation |
According to reports, leucine proanthocyanidins are found in madder, Rubia agi, Rubia valicina, and other organisms with available data.
Lucidin primeveroside (Lucidin 3-O-β-primeveroside) (CAS#: 29706-59-0) is an anthraquinone glycoside found in madder root. It has been used as a coloring agent and food additive and has demonstrated anti-inflammatory, antimicrobial, and cytotoxic properties. However, it induces DNA adduct formation and increases mutation frequencies in mice. This compound is not a drug and is a research chemical. |
| Molecular Formula |
C26H28O14
|
|---|---|
| Molecular Weight |
564.49
|
| Exact Mass |
564.148
|
| CAS # |
29706-59-0
|
| PubChem CID |
160180
|
| Appearance |
Light yellow to yellow solid powder
|
| Melting Point |
210-212 °C
|
| LogP |
-2.1
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
40
|
| Complexity |
918
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(C(=C4C(=C3)C(=O)C5=CC=CC=C5C4=O)O)CO)O)O)O)O)O)O
|
| InChi Key |
NVKNRXOMCYTFJF-WFLOGZPDSA-N
|
| InChi Code |
InChI=1S/C26H28O14/c27-6-12-14(5-11-16(19(12)31)18(30)10-4-2-1-3-9(10)17(11)29)39-26-24(36)22(34)21(33)15(40-26)8-38-25-23(35)20(32)13(28)7-37-25/h1-5,13,15,20-28,31-36H,6-8H2/t13-,15-,20+,21-,22+,23-,24-,25+,26-/m1/s1
|
| Chemical Name |
1-hydroxy-2-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyanthracene-9,10-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7715 mL | 8.8576 mL | 17.7151 mL | |
| 5 mM | 0.3543 mL | 1.7715 mL | 3.5430 mL | |
| 10 mM | 0.1772 mL | 0.8858 mL | 1.7715 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
